Our aim was to identify genes that influence the inverse association of coffee with the risk of developing Parkinson's disease (PD). We used genome-wide genotype data and lifetime caffeinated-coffee-consumption data on 1,458 persons with PD and 931 without PD from the NeuroGenetics Research Consortium (NGRC), and we performed a genome-wide association and interaction study (GWAIS), testing each SNP's main-effect plus its interaction with coffee, adjusting for sex, age, and two principal components. We then stratified subjects as heavy or light coffee-drinkers and performed genome-wide association study (GWAS) in each group. We replicated the most significant SNP. Finally, we imputed the NGRC dataset, increasing genomic coverage to examine the region of interest in detail. The primary analyses (GWAIS, GWAS, Replication) were performed using genotyped data. In GWAIS, the most significant signal came from rs4998386 and the neighboring SNPs in GRIN2A. GRIN2A encodes an NMDA-glutamate-receptor subunit and regulates excitatory neurotransmission in the brain. Achieving P2df = 10−6, GRIN2A surpassed all known PD susceptibility genes in significance in the GWAIS. In stratified GWAS, the GRIN2A signal was present in heavy coffee-drinkers (OR = 0.43; P = 6×10−7) but not in light coffee-drinkers. The a priori Replication hypothesis that “Among heavy coffee-drinkers, rs4998386_T carriers have lower PD risk than rs4998386_CC carriers” was confirmed: ORReplication = 0.59, PReplication = 10−3; ORPooled = 0.51, PPooled = 7×10−8. Compared to light coffee-drinkers with rs4998386_CC genotype, heavy coffee-drinkers with rs4998386_CC genotype had 18% lower risk (P = 3×10−3), whereas heavy coffee-drinkers with rs4998386_TC genotype had 59% lower risk (P = 6×10−13). Imputation revealed a block of SNPs that achieved P2df<5×10−8 in GWAIS, and OR = 0.41, P = 3×10−8 in heavy coffee-drinkers. This study is proof of concept that inclusion of environmental factors can help identify genes that are missed in GWAS. Both adenosine antagonists (caffeine-like) and glutamate antagonists (GRIN2A-related) are being tested in clinical trials for treatment of PD. GRIN2A may be a useful pharmacogenetic marker for subdividing individuals in clinical trials to determine which medications might work best for which patients.
Vyšlo v časopise: Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene as a Parkinson's Disease Modifier Gene via Interaction with Coffee. PLoS Genet 7(8): e32767. doi:10.1371/journal.pgen.1002237 Kategorie: Research Article prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002237
1. ManolioTACollinsFSCoxNJGoldsteinDBHindorffLA 2009 Finding the missing heritability of complex diseases. Nature 461 747 753
2. ThomasD 2010 Gene–environment-wide association studies: emerging approaches. Nat Rev Genet 11 259 272
3. DorseyERConstantinescuRThompsonJPBiglanKMHollowayRG 2007 Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68 384 386
4. HardyJ 2010 Genetic analysis of pathways to Parkinson disease. Neuron 68 201 206
5. HamzaTHZabetianCPTenesaALaederachAMontimurroJ 2010 Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42 781 785
6. SatakeWNakabayashiYMizutaIHirotaYItoC 2009 Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41 1303 1307
7. Simon-SanchezJSchulteCBrasJMSharmaMGibbsJR 2009 Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41 1308 1312
8. PankratzNWilkJBLatourelleJCDeStefanoALHalterC 2009 Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124 593 605
9. EdwardsTLScottWKAlmonteCBurtAPowellEH 2010 Genome-Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease. Ann Hum Genet 74 97 109
10. NallsMAPlagnolVHernandezDGSharmaMSheerinUM 2011 Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377 641 649
11. HernanMATakkoucheBCaamano-IsornaFGestal-OteroJJ 2002 A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52 276 284
12. PowersKKayDFactorSZabetianCHigginsD 2008 Combined effects of smoking, coffee and NSAIDs on Parkinson's disease risk. Mov Disord 23 88 95
13. CostelloSCockburnMBronsteinJZhangXRitzB 2009 Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 169 919 926
14. McCullochCCKayDMFactorSASamiiANuttJG 2008 Exploring gene-environment interactions in Parkinson's disease. Hum Genet 123 257 265
15. KraftPYenYCStramDOMorrisonJGaudermanWJ 2007 Exploiting gene-environment interaction to detect genetic associations. Hum Hered 63 111 119
16. ChenJFXuKPetzerJPStaalRXuYH 2001 Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21 RC143
17. LeWittPAGuttmanMTetrudJWTuitePJMoriA 2008 Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63 295 302
18. FernandezHHGreeleyDRZweigRMWojcieszekJMoriA 2010 Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 16 16 20
19. Simon-SanchezJScholzSMatarin MdelMFungHCHernandezD 2008 Genomewide SNP assay reveals mutations underlying Parkinson disease. Hum Mutat 29 315 322
20. RitzBRManthripragadaADCostelloSLincolnSJFarrerMJ 2009 Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ Health Perspect 117 964 969
21. ChenHHuangXGuoXMailmanRBParkY 2010 Smoking duration, intensity, and risk of Parkinson disease. Neurology 74 878 884
22. HughesAJDanielSEBen-ShlomoYLeesAJ 2002 The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 861 870
23. HancockDBMartinERStajichJMJewettRStacyMA 2007 Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 64 576 580
24. ThompsonFEKipnisVMidthuneDFreedmanLSCarrollRJ 2008 Performance of a food-frequency questionnaire in the US NIH-AARP (National Institutes of Health-American Association of Retired Persons) Diet and Health Study. Public Health Nutr 11 183 195
25. ManningAKLaValleyMLiuCTRiceKAnP 2010 Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP×environment regression coefficients. Genet Epidemiol 35 11 18
26. AschardHHancockDBLondonSJKraftP 2011 Genome-wide meta-analysis of joint tests for genetic and gene-environment interaction effects. Hum Hered 70 292 300
27. PurcellSNealeBTodd-BrownKThomasLFerreiraMA 2007 PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81 559 575
28. NeterJKunterMNachtsheimCWassermanW 1996 Applied Linear Statistical Models. 52 53
29. GaoXBeckerLCBeckerDMStarmerJDProvinceMA 2010 Avoiding the high Bonferroni penalty in genome-wide association studies. Genet Epidemiol 34 100 105
30. HowieBNDonnellyPMarchiniJ 2009 A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5 e1000529 doi:10.1371/journal.pgen.1000529
31. BarrettJCFryBMallerJDalyMJ 2005 Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 263 265
32. LinDYHuangBE 2007 The use of inferred haplotypes in downstream analyses. Am J Hum Genet 80 577 579
33. WangKLiMHadleyDLiuRGlessnerJ 2007 PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 17 1665 1674
34. ZabetianCPHutterCMYearoutDLopezANFactorSA 2006 LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79 752 758
35. EvansAHLawrenceADPottsJMacGregorLKatzenschlagerR 2006 Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 77 317 321
36. LevranOLondonoDO'HaraKRandesiMRotrosenJ 2009 Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav 8 531 540
37. VinkJMSmitABde GeusEJSullivanPWillemsenG 2009 Genome-wide association study of smoking initiation and current smoking. Am J Hum Genet 84 367 379
38. DorusSVallenderEJEvansPDAndersonJRGilbertSL 2004 Accelerated evolution of nervous system genes in the origin of Homo sapiens. Cell 119 1027 1040
39. ShenWFlajoletMGreengardPSurmeierDJ 2008 Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321 848 851
40. JinXCostaRM 2010 Start/stop signals emerge in nigrostriatal circuits during sequence learning. Nature 466 457 462
41. HigleyMJSabatiniBL 2010 Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 13 958 966
42. CaudleWMZhangJ 2009 Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol 220 230 233
43. BirneyEStamatoyannopoulosJADuttaAGuigoRGingerasTR 2007 Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447 799 816
44. SuAIWiltshireTBatalovSLappHChingKA 2004 A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101 6062 6067
45. BlandiniFNappiGGreenamyreJT 2001 Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol 49 525 529
46. SchwarzschildMAXuKOztasEPetzerJPCastagnoliK 2003 Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 61 S55 61
47. TebanoMTPintorAFrankCDomeniciMRMartireA 2004 Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre - and postsynaptic sites in the rat striatum. J Neurosci Res 77 100 107
48. ShoulsonIPenneyJMcDermottMSchwidSKaysonE 2001 A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 56 455 462
49. ArningLSaftCWieczorekSAndrichJKrausPH 2007 NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet 122 175 182
50. AndresenJMGayanJChernySSBrocklebankDAlkorta-AranburuG 2007 Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet 44 44 50
51. ItokawaMYamadaKYoshitsuguKToyotaTSugaT 2003 A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 13 271 278
52. EndeleSRosenbergerGGeiderKPoppBTamerC Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 42 1021 1026
Zvýšte si kvalifikáciu online z pohodlia domova
Nemáte účet? Registrujte sa
Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.
